撒哈拉以南非洲需放射治疗的临床试验中的质量保证
本文回顾了南非和津巴布韦2个中心开展的AMC-081多中心研究(HIV感染局部晚期宫颈癌女性接受顺铂联合放疗)中,IROC对放疗中心认证和质量保证的审核过程。38例入组女性均接受±5%方案规定外照射剂量,所有近距离治疗施源器放置几何评分均符合方案,但超过50%的植入中A点、B点、ICRU膀胱或直肠剂量需IROC纠正,最终58%按方案治疗、40%有小方案偏离、3%有大方案偏离,且无记录在方案要求的治疗完成后60天内提交。作者结论为大方案偏离低,但放疗数据未及时提交,未来研究需确保及时充分的质量保证路径。
要点
- 38例均接受±5%方案规定外照射剂量,所有近距离治疗施源器放置几何评分符合方案。
- 超过50%的植入中A点、B点、ICRU膀胱或直肠剂量需IROC纠正。
- 最终58%按方案治疗、40%有小方案偏离、3%有大方案偏离,无记录在60天内提交。
核心结论
- 大方案偏离低,但放疗数据未及时提交。
- 未来研究尤其含立体定向或调强放疗等特殊技术者,需确保及时充分质量保证的路径。
研究设计与样本
- 对AMC-081多中心研究中放疗中心认证和放疗质量保证的IROC审核过程进行回顾。
- 研究对象为南非和津巴布韦2个中心新诊断的IB2、IIA(>4 cm)、IIB-IVA期宫颈癌(按2009年FIGO分期)HIV感染女性。
主要发现
- 38例入组女性均接受±5%方案规定外照射剂量的盆腔三维适形放疗(41.4-45 Gy)。
- 所有近距离治疗植入的施源器放置几何评分均按方案判定。
- 超过50%的近距离治疗植入中A点、B点、ICRU膀胱或直肠剂量需IROC纠正。
- 最终评估中58%(n=22)按方案治疗,40%(n=15)有小方案偏离,3%(n=1)有大方案偏离。
- 无记录在方案要求的治疗完成后60天内收到。
关键数值与推荐
- 外照射放疗为盆腔三维适形放疗41.4-45 Gy,使用直线加速器。
- 近距离治疗为高剂量率,每次A点6-9 Gy,最多4次。
- 同步每周顺铂40 mg/m2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Given the increasing availability of radiation therapy in sub-Saharan Africa, clinical trials that include radiation therapy are likely to grow. Ensuring appropriate delivery of radiation therapy through rigorous quality assurance is an important component of clinical trial execution. We reviewed the process for credentialing radiation therapy sites and radiation therapy quality assurance through the Imaging and Radiation Oncology Core (IROC) Houston Quality Assurance Center for AIDS Malignancy Consortium (AMC)-081, a multicenter study of cisplatin and radiation therapy for women with locally advanced cervical cancer living with HIV, conducted by the AIDS Malignancy Consortium at 2 sites in South Africa and Zimbabwe. METHODS AND MATERIALS: Women living with HIV with newly diagnosed stage IB2, IIA (>4 cm), IIB-IVA cervical carcinoma (per the 2009 International Federation of Gynecology and Obstetrics [FIGO] staging classifications) were enrolled in AMC-081. They received 3-dimensional conformal external beam radiation therapy (EBRT) to the pelvis (41.4-45 Gy) using a linear accelerator, high-dose-rate brachytherapy (6-9 Gy to point A with each fraction and up to 4 fractions), and concurrent weekly cisplatin (40 mg/m2). IROC reviewed EBRT and brachytherapy quality assurance records after treatment. RESULTS: All of the 38 women enrolled in AMC-081 received ±5% of the protocol-specified prescribed dose of EBRT. Geometry of brachytherapy applicator placement was scored as per protocol in all implants. Doses to points A and B, International Commission on Radiation Units and Measurements (ICRU) bladder, or ICRU rectum required correction by IROC in >50% of the implants. In the final evaluation, 58% of participants (n = 22) were treated per protocol, 40% (n = 15) had minor protocol deviations, and 3% (n = 1) had major protocol deviations. No records were received within 60 days of treatment completion as requested in the protocol. CONCLUSIONS: Major radiation therapy deviations were low, but timely submission of radiation therapy data did not occur. Future studies, especially those that include specialized radiation therapy techniques such as stereotactic or intensity-modulated radiation therapy, will require pathways to ensure timely and adequate quality assurance.
引用
- Lin LL, Ndlovu N, Lowenstein J, et al. Quality Assurance in Clinical Trials Requiring Radiation Therapy in Sub-Saharan Africa. Int J Radiat Oncol Biol Phys. 2022. PMID: 36493958. doi:10.1016/j.ijrobp.2022.11.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。